Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is an Epstein-Barr virus (EBV) associated disease⁎,⁎⁎

Dear Editor,

We present a 12-year-old Hispanic male with a 6-year history of "nodules" that ulcerated in the face, lower and upper limbs which left multiple scars. He attended for 20-days of facial edema, associated with a decrease in visual acuity. The ophthalmologist reported necrosis of the left eye. During the physical examination he presented periorbital edema, left frontal vesico-blisters, which left varioliform scars (Fig. 1). A skin biopsy was performed with evidence of epidermal necrosis, atypical perivascular, and perianexial lymphoid infiltrates with angiocentricity. Immunohistochemistry was compatible with cytotoxic T lymphocytes (CD3+ CD8+ Perforin+ CD56-) with a 20% of ki67, and a positive in situ hybridization for Epstein-Barr virus (EBER) test (Figs. 2 and 3). A conjunctiva biopsy was performed, with evidence of necrotic tissue, and a positive polymerase chain reaction for EBV. Viral load for EBV in blood was positive (197,929 copies/mL). With all of the above, a diagnosis of HV-LPD was performed. CT scans report cervical adenopathies and hepatosplenomegaly. Biopsy of cervical node and bone marrow was negative for malignancy. Proper

References


Agenes Carvalho Andrade 1,*, Marina Zoéga Hayashida 1, Milvia Maria Simões e Silva Enokihara 2, Sérgio Henrique Hirata 2

Department of Dermatology, Universidade Federal São Paulo, São Paulo, SP, Brazil

⁎ Corresponding author.

E-mail address: dra.agnesandrade@gmail.com (A.C. Andrade).

Received 20 November 2019; accepted 30 June 2020
Available online 15 March 2021

How to cite this article: Ordoñez-Parra J, Mejia Cortes M, Tamayo-Buendia MM, Infante Gómez AM. Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is an Epstein-Barr virus (EBV) associated disease. An Bras Dermatol. 2021;96:388–90.

⁎⁎ Study conducted at the Hospital Universitario San Ignacio, Bogotá, Colombia.

Figure 3 Dermoscopy after removal of crusts, displaying glomerular vessels.

Conflicts of interest

None declared.
In children, has a papulovesicular eruption with a crusted center, and posterior varioliforme scarring. Nonetheless, its localization is limited to sun-exposed areas, with no facial edema nor systemic compromise. Histologic differential diagnosis includes other lymphomas associated with EBV. For example, nasal NK lymphoma is characterized by a rapidly progressive clinical course, positive CD56 and negative CD8 on the immunohistochemistry.

There are no treatment guidelines due to the rarity of the disease. Beltran et al. consider thalidomide as a useful treatment, due to its anti-inflammatory and antiproliferative properties. Four Peruvian patients received thalidomide 100 mg orally daily with different results. We report a 12-month clinical remission in our patient, following thalidomide treatment, supporting the use of it as a first-line immunomodulating agent.

**Financial support**

None declared.

**Authors’ contributions**

Juliana Ordoñez-Parra: Patient assessment; literature review; manuscript creation.

Maddy Mejía Cortes: Patient assessment; literature review; manuscript creation.

Margarita Tamayo-Buendía: Patient assessment; literature review; manuscript creation.

Ana María Infante Gómez: Patient assessment and literature review.

**Conflicts of interest**

None declared.

**References**

**N-acetylcysteine for managing neurotic excoriation: encouraging results in two patients**

**Dear Editor,**

Neurotic Excoriation (NE) is characterized by recurrent picking of skin, leading to cutaneous lesions ranging from superficial erosions to deep ulcerations.¹ Acne excoriée (AE) is a subset of NE in which the focus is on acne lesions. NE causes significant psychosocial impairment, which therefore necessitates an effective treatment.²,³ Although several approaches exist, including behavioral and pharmacological therapies, managing NE is still challenging.¹-³ Glutamatergic dysfunction and oxidative stress are thought to contribute to the pathophysiology of NE.²,³ Recently, N-Acetylcysteine (NAC), a glutamate modulator and an antioxidant, has been proposed as a promising treatment alternative for NE, and a limited number of reports have shown encouraging results.¹-⁵

A 75-year-old woman presented with a 5-year history of itching and scattered wounds on her legs. She had been feeling an irresistible urge to pick her skin, which then became a daily routine that ensued self-inflicted lesions on otherwise normal-appearing skin. Dermatologic examination revealed multiple irregularly shaped erythematous or hyperpigmented, eroded, excoriated, or lichenified papules and nodules of varying size on both legs (Fig. 1A). Complete blood cell count and liver, renal and thyroid function test results were within normal limits. The second case was a 36-year-old woman who presented with a 3-month history of itchy acne-like lesions on her face. She had used many dermocosmetic products without success. She had been habitually picking, scratching, and squeezing these lesions, and despite these repeated efforts, she was unable to resist this behavior. Dermatologic examination revealed a few comedones, erythematous and excoriated papules, as well as hyperpigmented macules on the forehead (Fig. 2A).

Tzanck smears taken from the lesions stained with May-Grünwald-Giemsa showed no pathology. Upon the diagnosis of NE and AE, respectively, both patients were started on NAC (1200 mg/d, p.o.). The clinical findings subsided after 2- and 6-weeks, in the first (Fig. 1B) and second (Fig. 2B) patient, respectively. No side effects were observed and both patients no longer displayed self-excoriation behavior. The treatment lasted 3-months and 6-weeks, and after cessation of therapy no relapse was observed in 6- and 3-months follow-up in the NE and AE patient, respectively.

There are only a few case reports and two studies in the literature that indicate the potential benefit of NAC for treating NE.¹-⁵ In those reports, NAC dosage and treatment duration varied greatly (450–3000 mg/d and 1-10 months).²,³ Side effects including gastrointestinal upset, dry mouth, and dizziness were rarely observed and did not require cessation of therapy.²,³ Nevertheless, the follow-up data regarding the relapse risk after discontinuation of NAC are unknown.

NE is a psychocutaneous disorder, and given that those patients usually present to dermatology clinics, not only the psychiatrists but also the dermatologists should be aware of new treatment options. Our experience in the present two cases supports the notion that NAC could be a safe and effective alternative for managing NE. However, the appropriate NAC dose and treatment duration for NE, as well as the relapse risk of skin picking behavior after the cessation of therapy, still require clarification in future studies.

**Financial support**

None declared.

**Authors’ contributions**

Deren Özcan: The conception and design of the study; acquisition of data; analysis and interpretation of data; drafting

---

² How to cite this article: Özcan D. N-acetylcysteine for managing neurotic excoriation: encouraging results in two patients. An Bras Dermatol. 2021;96:390-1.

²² Study conducted at the Department of Dermatology, Faculty of Medicine, Başkent University, Ankara, Turkey.